DIOCLES: Some Caveats and New Questions. Response

To the Editor,

On behalf of the Scientific Committee and researchers of the DIOCLES registry,1 we wish to thank Rosell-Ortiz et al for their letter and their interest in our study. The results are certainly promising in that they show a decrease in the in-hospital and 6-month mortality rates among patients with acute coronary syndrome (ACS) with respect to that recorded in the MASCARA study, the most recent large registry carried out in Spain,2 and are in accordance with the progressive reduction in mortality due to ST-segment elevation acute myocardial infarction (STEMI) observed over the past 20 years. Undoubtedly, a number of factors have influenced this reduction, and the development of out-of-hospital emergency services is probably not the least important of them. Closely related to the latter aspect is the progressive incorporation of protocol-based networks for the management of patients with STEMI, in which prehospital care plays a major role.4,5 We agree with the authors of the letter in that the overall mortality occurring during the acute phase of STEMI is higher than the 6.6% recorded in our study,1 as this value does not take into account prehospital mortality, both to ensure coherence for comparison with previous registries2,3 and because it is very difficult to reliably estimate its incidence.

We did not examine the possible differences in mortality in the overall group of ACS patients or specifically in those who also had STEMI in terms of the level of care provided by hospitals or the Spanish autonomous community, aspects of unquestionable interest.6 We will attempt to analyze the data from the DIOCLES registry in this respect, but the relatively small size of the population, especially in the subgroup with STEMI, will probably make it impossible to draw firm conclusions. In this subgroup, the overall management strategy applied is almost certainly more relevant than the technological level of the treatment hospital. Extensive evidence indicates that the development of efficient regional networks to care for patients with STEMI, and that include both primary percutaneous coronary intervention and a pharmacoinvasive strategy when this intervention cannot be performed promptly, improves the percentage of reperfused patients and decreases infarction-related mortality. It was not our objective (nor is the sample size large enough) to compare the mortality rate of the patients initially treated with thrombolysis with that of those whose initial treatment was primary percutaneous coronary intervention. In any case, the results of the DIOCLES registry show that, in Spain, there is margin for improvement in the application of both reperfusion strategies.1 As is logical, care provided by an out-of-hospital emergency service was associated with a more frequent use of prehospital thrombolysis (48%), especially if the treatment was administered in a fully-equipped ambulance (56%). However, even in this setting, a significant number of patients underwent thrombolysis in the hospital.

The DIOCLES data coincide with those of previous studies2 in that the patients with unclassified ACS constitute the subgroup at highest risk, and we consider the attempt to identify the determinants of this greater risk, especially the modifiable factors, to be highly relevant. We appreciate the proposal of Rosell-Ortiz et al to carry out an in-depth analysis of the data in this respect.

José A. Barrabés,⁎⁎ and Alfredo Bardaji⁎,⁎

⁎Principal investigators DIOCLES study
⁎⁎Servicio de Cardiología, Hospital Universitario Vall d’Hebron, VHIR, Universidad Autónoma de Barcelona, Barcelona, Spain
⁎⁎Servicio de Cardiología, Hospital Universitario de Tarragona Joan XXIII, IISPV, Universidad Rovira i Virgili, Tarragona, Spain

⁎ Corresponding author:
E-mail address: jabarrabes@vhebron.net (J.A. Barrabés).

Available online 6 December 2014

REFERENCES


SEE RELATED ARTICLE:
http://dx.doi.org/10.1016/j.rec.2014.08.012
http://dx.doi.org/10.1016/j.rec.2014.09.013

Comments on Exercise Echocardiography and Multidetector Computed Tomography for the Evaluation of Acute Chest Pain

Comentarios a la evaluación del dolor torácico agudo mediante ecocardiografía de ejercicio y tomografía computarizada multidetectores

To the Editor,

I have read the article published by the group at the Hospital Clínic de Barcelona1 with great interest, and would like to congratulate the authors publically on their outstanding research endeavor.

Nonetheless, although the authors recommend “a balanced strategy” combining both techniques, in my reading of the article I detect an underlying conflict between them, and would like to make some comments related to this. These comments are intended in no way to diminish the authors’ extraordinary work, but rather to present “the current value” of computed tomography (CT).

1. A limitation not mentioned by the authors is the long time elapsed between the conduct of the study and its publication. It may be that the intervening 6 years have brought no changes in exercise echocardiography and that older results thus remain applicable in 2014; however, developments in multidetector computed tomography (MDCT) during this period have been truly spectacular and exponential. Besides improved spatial and
temporal resolution and reduced radiation doses, these developments include the introduction of complementary explorations for the detection of ischemia (perfusion, noninvasive determination of functional repercussion of stenosis, etc.). These advances have made MDCT one of the most sensitive and specific methods for ruling out significant coronary artery disease, second only to invasive coronary angiography. The noninvasive nature of MDCT moreover brings added benefits, including the detection of subclinical coronary artery disease, the potential to characterize high-risk plaques, and prognostic value.

2. Technical considerations. The diagnostic performance of MDCT could have been improved with an optimized spatial resolution of the reconstructions, achievable by modifying the slice thickness, the between-slice increase and filters as described by other authors working with exactly the same type of scanner. Additionally, given the mean body surface area observed in the study population (although the benchmark parameter in cardiac CT is body-mass index), a tube potential of 100 kV would have improved luminal contrast in the coronary arteries, thereby facilitating image interpretation and exponentially reduces the radiation dose. Such dose reductions are line with Society of Cardiovascular Computed Tomography guidelines, which recommend the establishment of quality assurance procedures to meet the following objectives: sufficient diagnostic quality in ≥95% of scans, a demonstrable diagnostic accuracy at least 75% that of invasive coronary angiography, and a mean radiation dose at the reference level (12 mSv according to the most recent guidelines). Today, with a careful acquisition protocol and the latest scanners, doses are normally in the region of 1-2 mSv or even lower, well below the 7-10 mSv in invasive coronary angiography and the 8-10 mSv in isotope studies with gamma radiation, demonstrated to be more harmful than X rays.

3. Methodological considerations. An Agatston score >400 is not equivalent to the detection of significant coronary artery disease by MDCT because this threshold drags down the specificity of the method, with 20% of patients with this score having no disease. The authors’ statement in the Discussion that “MDCT has low diagnostic specificity” seems to me to be inappropriate. What limits specificity is setting the significance threshold at ≥50% when the “reference pattern” is ≥70% for invasive coronary angiography (luminogram) and MDCT is based on this same “luminogram”, with the advantage of assessing the coronary wall. The ≥50% significance threshold was established in the cited study by Hoffmann, in which final cost-effectiveness did not reach statistical significance. In contrast, the Goldstein study, using a significance threshold of ≥70%, showed a significantly positive cost-effectiveness for MDCT ($2137 for MDCT compared with $3458 for standard; P < .0001).

The major scientific societies now accept the diagnostic value of both techniques and their complementary nature, especially in non-diagnostic MDCT studies and studies that indirectly evaluate the functional repercussion of intermediate or limiting stenosis, an evaluation achieved directly with pressure guides in invasive coronary angiography.

Paz Catalán-Sanz

Certificación en la Subespecialidad de Tomografía Computarizada Cardiovascular (CBCCT); Cardiovascular Healthcare Innovation, Madrid, Spain

E-mail address: pazcatalan@secardiologia.es

Available online 15 December 2014

REFERENCES


SEE RELATED ARTICLES:
http://dx.doi.org/10.1016/j.rec.2014.10.004
http://dx.doi.org/10.1016/j.rec.2014.05.009
http://dx.doi.org/10.1016/j.rec.2014.09.014